A 2023 ACMG review and clinical guidance for individuals with heterozygous CHEK2 variants2 noted a single publication of nonsignificant CHEK2-associated bladder cancer28 but deemed this evidence insufficient to make recommendations; more recent publications have found additional evidence of a CHEK2-bladder cancer association.29,30 Genomic ascertainment in this study revealed similarly increased bladder cancer risk in both cohorts (especially in the PTV groups). This evidence concerns the gene CHEK2 and urinary bladder cancer.